Who is sponsoring NCT03704181?

NCT03704181 is sponsored by University of Sao Paulo General Hospital.

What drugs are being tested in NCT03704181?

Interventions in NCT03704181: Colchicine 0.5 MG twice day for one year, Placebo Oral Tablet.

What condition does NCT03704181 study?

NCT03704181 studies Chagas Disease, Colchicine Resistance.

Is NCT03704181 still recruiting?

NCT03704181 is currently status unknown. Last updated 11 March 2019.

Last reviewed 2019-03-11 · How we verify

NCT03704181: COACH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Colchicine for Patients With Chagas´ Disease( B1 Stage)

Status unknown Phase 2 Last updated 11 March 2019

What this trial tests

Phase 2 trial testing Colchicine 0.5 MG twice day for one year in Chagas Disease in 60 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
30 December 2020

5 January 2021

Quick facts

Lead sponsor	University of Sao Paulo General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 October 2018
Primary completion	30 December 2020
Estimated completion	5 January 2021
Sites	1 location across Brazil

Drugs / interventions tested

Colchicine 0.5 MG twice day for one year — full drug profile →
Placebo Oral Tablet — full drug profile →

Conditions studied

Chagas Disease — all drugs for Chagas Disease →
Colchicine Resistance — all drugs for Colchicine Resistance →

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 18 to 70, any sex, with Chagas Disease or Colchicine Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluate the addition of colchicine in the treatment of patients with Chagas´disease. Forty patients will receive colchicine while twenty patients will receive placebo

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Adding insult to injury - Inflammation at the heart of cardiac fibrosis.
Smolgovsky S, Ibeh U, Tamayo TP, Alcaide P. · · 2021 · cited 55× · PMID 33166625 · DOI 10.1016/j.cellsig.2020.109828
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens.
Karatza E, Ismailos G, Karalis V. · · 2021 · cited 26× · PMID 33845715 · DOI 10.1080/00498254.2021.1909782
Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery.
Mansoldo FRP, Carta F, Angeli A, Cardoso VDS, et al · · 2020 · cited 25× · PMID 33238613 · DOI 10.3390/molecules25225483
Clinical trials for Chagas disease: etiological and pathophysiological treatment.
Gonzaga BMS, Ferreira RR, Coelho LL, Carvalho ACC, et al · · 2023 · cited 10× · PMID 38188583 · DOI 10.3389/fmicb.2023.1295017
Trypanosomatid-Caused Conditions: State of the Art of Therapeutics and Potential Applications of Lipid-Based Nanocarriers.
Muraca G, Berti IR, Sbaraglini ML, Fávaro WJ, et al · · 2020 · cited 8× · PMID 33324615 · DOI 10.3389/fchem.2020.601151

Verify or expand the search:

Other recruiting trials for Chagas Disease

Currently open trials in the same condition.

NCT06632600 — A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. · Phase 2 · recruiting
NCT04897516 — Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease · Phase 3 · recruiting
NCT04984265 — SBRT in Chagas Disease Ventricular Tachycardia · Phase 1, PHASE2 · active not recruiting
NCT04024163 — Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease · Phase 3 · active not recruiting

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03704181 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
Last refreshed: 11 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing